Abstract
Information regarding the comparative efficacy and safety of first-generation treatments for Neurotrophic Tropomyosin Receptor Kinase (NTRK) fusion cancer is limited. Although cross-trial comparisons are subject to potential biases, a matching-adjusted indirect comparison (MAIC) can balance observed population characteristics to facilitate comparisons between trials. This study compared larotrectinib and entrectinib using MAIC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
